blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3634486

EP3634486 - ENGINEERED MULTISPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRICAL CH2-CH3 REGION MUTATIONS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  13.03.2020
Database last updated on 15.06.2024
FormerThe international publication has been made
Status updated on  15.12.2018
Most recent event   Tooltip13.05.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Janssen Biotech, Inc.
800/850 Ridgeview Drive
Horsham, PA 19044 / US
[2020/16]
Inventor(s)01 / CHIU, Mark
200 Great Valley Parkway
Malvern, PA 19355 / US
02 / ZWOLAK, Adam
1400 McKean Road
Spring House, PA 19477 / US
 [2020/16]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2020/16]Duffield, Stephen
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date18814314.304.06.2018
[2020/16]
WO2018IB53997
Priority number, dateUS201762515316P05.06.2017         Original published format: US 201762515316 P
[2020/16]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2018224951
Date:13.12.2018
Language:EN
[2018/50]
Type: A2 Application without search report 
No.:EP3634486
Date:15.04.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 13.12.2018 takes the place of the publication of the European patent application.
[2020/16]
Search report(s)International search report - published on:US14.02.2019
(Supplementary) European search report - dispatched on:EP02.03.2021
ClassificationIPC:A61K39/395, C12N15/09, C12N5/10, C07K16/12, C07K16/46
[2020/16]
CPC:
C07K16/468 (EP,KR,US); C07K16/1027 (EP,KR,US); C07K16/1063 (EP,KR,US);
C07K16/241 (EP,KR,US); C07K16/2809 (EP,KR,US); C07K16/46 (EP,KR,US);
C07K2317/31 (EP,KR,US); C07K2317/515 (EP,US); C07K2317/524 (EP,KR,US);
C07K2317/526 (EP,KR,US); C07K2317/70 (EP,KR,US); C07K2317/72 (EP,KR,US);
C07K2317/94 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/16]
TitleGerman:GENTECHNISCH HERGESTELLTE MULTISPEZIFISCHE ANTIKÖRPER UND ANDERE MULTIMERE PROTEINE MIT ASYMMETRISCHEN MUTATIONEN DER CH2-CH3-REGION[2020/16]
English:ENGINEERED MULTISPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRICAL CH2-CH3 REGION MUTATIONS[2020/16]
French:ANTICORPS MULTISPÉCIFIQUES MODIFIÉS ET AUTRES PROTÉINES MULTIMÈRES AVEC DES MUTATIONS DE RÉGION CH2-CH3 ASYMÉTRIQUES[2020/16]
Entry into regional phase03.01.2020National basic fee paid 
03.01.2020Search fee paid 
03.01.2020Designation fee(s) paid 
03.01.2020Examination fee paid 
Examination procedure03.01.2020Examination requested  [2020/16]
29.09.2021Amendment by applicant (claims and/or description)
Fees paidRenewal fee
31.03.2020Renewal fee patent year 03
14.06.2021Renewal fee patent year 04
31.03.2022Renewal fee patent year 05
31.03.2023Renewal fee patent year 06
13.05.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2006020114  (APPLIED MOLECULAR EVOLUTION [US], et al) [X] 5-7,10 * page 125 - page 126 * [I] 1-4,8,9,11-16;
 [XI]WO2006053301  (XENCOR INC [US], et al) [X] 5-7,10 * claims 1, 6 * [I] 1-4,8,9,11-16;
 [A]WO2009058492  (XENCOR INC [US], et al) [A] 1 * Last lines of example 11 *;
 [XI]WO2016098357  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [X] 5-7,10 * Table 28 on page 204, compound with reference to SEQ ID NO: 262 * [I] 1-4,8,9,11-16;
 [A]WO2017036905  (UCB BIOPHARMA SPRL [BE]) [A] 1 * claims 1, 9, 10 *;
 [XP]  - ADAM ZWOLAK ET AL, "Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding", SCIENTIFIC REPORTS, (20171114), vol. 7, no. 1, doi:10.1038/s41598-017-15748-0, pages 1 - 11, XP055574512 [XP] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1038/s41598-017-15748-0
International search[A]WO2007143098  (AVEO PHARMACEUTICALS INC [US], et al) [A] 44-46 * ; paragraph [0262] *;
 [A]US2012116057  (KANNAN GUNASEKARAN [US], et al) [A] 1-5, 17-20, 23-24, 25/22-24, 29-33, 48-49, 50/48-49, 51/50/48-49, 52/51/50/48-49, 60-61, 64-66, 67/64-66, 75-79 * ; paragraph [0012] *;
 [A]WO2015158867  (UCB BIOPHARMA SPRL [BE]) [A] 1-5, 17-20, 23-24, 25/22-24, 29-33, 40-41, 42/40-41, 48-49, 50/48-49, 51/50/48-49, 52/51/50/48-49, 60-61, 64-66, 67/64-66, 75-79 * ; page 4, line 31; page 8, line 1; page 18, lines 8-9; page 19, lines 8-10; claim 34 *;
 [A]WO2017034770  (BISON THERAPEUTICS INC [US]) [A] 1-5, 17-20, 23-24, 25/22-24, 29-33, 48-49, 50/48-49, 51/50/48-49, 52/51/50/48-49, 60-61, 64-66, 67/64-66, 75-79 * ; page 5, lines 8-10; page 12, lines 9-15; page 17, line 8 *;
 [A]WO2017011342  (ABBVIE INC [US]) [A] 1-5, 17-20, 23-24, 25/22-24, 29-33, 48-49, 50/48-49, 51/50/48-49, 52/51/50/48-49, 60-61, 64-66, 67/64-66, 75-79 * ; page 3, lines 11-23 *;
 [A]  - NIRANJANA, KRP , "Fc IgG1 heavy chain constant region, partial [Homo sapiens)", (20110706), page 1, NCBI, URL: https://www.ncbi.nlm.nih.gov/protein/AEV43323.1/, (20181016), XP055540699 [A] 1-5, 23-24, 25/22-24, 29-33, 48-49, 50/48-49, 51/50/48-49, 52/51/50/48-49, 60-61, 64-66, 67/64-66, 75-79
 [A]  - FUJIYAMA, K et al., "Homo sapiens mRNA for IgG H chain, Complete cds, clone: 231H5A11H", (20110717), pages 1 - 2, NCBI, URL: https://www.ncbi.nlm.nih.gov/nuccore/AB776838, XP055579870 [A] 17-20, 44-46
 [PX]  - ZWOLAK, A et al., "Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding", Scientific Reports, (20171200), vol. 7, no. 1, pages 1 - 11, XP055574512 [PX] 1-5, 17-20, 23-24, 25/22-24, 29-33, 48-49, 50/48-49, 51/50/48-49, 52/51/50/48-49, 60-61, 64-66, 67/64-66, 75-79 * ; whole document; DOI: 10.1038/s41598-017-15748-0 *

DOI:   http://dx.doi.org/10.1038/s41598-017-15748-0
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.